What is the appropriate Strattera (atomoxetine) dosing for a 15-year-old patient weighing 100 lb?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Strattera Dosing for 100 lb 15-Year-Old

For a 15-year-old weighing 100 lbs (45.4 kg), start Strattera at approximately 40 mg once daily in the morning, then titrate to a target dose of approximately 54 mg/day (1.2 mg/kg/day) after a minimum of 3 days, with a maximum dose not exceeding 63 mg/day (1.4 mg/kg/day or 100 mg/day, whichever is lower). 1

Dosing Algorithm

Initial Dosing:

  • Starting dose: 0.5 mg/kg/day × 45.4 kg = ~23 mg/day (round to available capsule strength: 25 mg)
  • Alternative conservative start: 40 mg once daily (approximately 0.9 mg/kg/day)
  • Administer as a single morning dose or split into morning and late afternoon/evening doses 1

Titration Schedule:

  • Wait minimum 3 days at starting dose before increasing 2
  • Target dose: 1.2 mg/kg/day × 45.4 kg = 54 mg/day (use 60 mg capsule as closest available strength)
  • This target dose has demonstrated optimal efficacy without additional benefit from higher doses 2, 3

Maximum Dose:

  • Absolute maximum: 1.4 mg/kg/day × 45.4 kg = 63.6 mg/day, not to exceed 100 mg/day 1
  • The 1.8 mg/kg/day dose (82 mg for this patient) provides no additional benefit over 1.2 mg/kg/day 2, 3

Critical Safety Monitoring

Before Starting Treatment:

  • Obtain detailed cardiac history: personal symptoms (chest pain, syncope, palpitations) and family history of sudden cardiac death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome 4
  • Baseline vital signs, height, and weight 4
  • Black Box Warning: Monitor closely for suicidal ideation, especially during the first few months and at dose changes 1, 2

Ongoing Monitoring:

  • Weekly contact during titration phase (2-4 weeks) 5
  • Monthly appointments until symptoms stabilized 5
  • Assess for common adverse effects: nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence 1
  • Weight at each visit to monitor appetite suppression 2

Important Clinical Considerations

Dosing Flexibility:

  • If gastrointestinal side effects occur, split the total daily dose into morning and evening administration 1
  • Evening-only dosing is an option if daytime sedation is problematic 1
  • Effects typically not observed until 6-12 weeks after initiation, unlike stimulants 1

Drug Interactions:

  • If patient is taking CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine), initial target should be 0.5 mg/kg/day with slower titration 1
  • Poor metabolizers (7% of population) have 10-fold higher drug levels and require dose adjustment 2

Growth Effects:

  • Weight and height gain may lag behind normative data for first 9-12 months, then rebounds 2
  • After 3 years, patients typically gain 0.5 kg more than predicted but 0.4 cm less in height 2

When to Consider Atomoxetine First-Line:

  • Comorbid tic disorders or Tourette's syndrome 1
  • Substance use disorder concerns 1
  • Stimulant intolerance or inadequate response 1
  • Need for 24-hour symptom coverage 1

Common Pitfalls to Avoid

  • Don't exceed 1.2 mg/kg/day initially - the 1.8 mg/kg/day dose shows no additional efficacy and may increase side effects 2, 3
  • Don't expect rapid response - unlike stimulants, full therapeutic effect requires 6-12 weeks 1
  • Don't abruptly discontinue - taper if stopping, though withdrawal syndrome is not typical 6
  • Don't ignore cardiovascular screening - obtain cardiac history before initiating 4
  • Don't miss suicidality monitoring - this is a black box warning requiring vigilant assessment 1, 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.